Real-world Impact of Treatment on Growth in Children With X-Linked Hypophosphatemia

20260 citationsJournal Articlehybrid Open Access

Authors

Seiji Fukumoto · Tokushima Hospital

Dieter Haffner · Medizinische Hochschule Hannover

Erik A. Imel · Indiana University – Purdue University Indianapolis

Keiichi Ozono

M L Brandi · Vita-Salute San Raffaele University

Haruka Ishii · Kyowa Kirin (Japan)

Zhiyi Li · Kyowa Kirin (France)

Abstract

Burosumab had a robust, positive association with improved growth outcomes in male and female children and adolescents with XLH. Modeling based on a median of 3.3 years of follow-up predicted burosumab can support improvement of growth that will likely result in greater adult height.

Topics & Keywords

Parathyroid Disorders and Treatments Bone health and treatments Magnesium in Health and Disease

Publication Details

Published in: The Journal of Clinical Endocrinology & Metabolism

DOI: 10.1210/clinem/dgag136

Field-Weighted Citation Impact: 0.00

Command Palette

Real-world Impact of Treatment on Growth in Children With X-Linked Hypophosphatemia

Authors

Abstract

Topics & Keywords

Publication Details